Original Article

You have full text access to this OnlineOpen article

Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01)†‡

  1. Maurizio Belfiglio M.D.,
  2. Miriam Valentini M.D.,
  3. Fabio Pellegrini M.Sc.,
  4. Giorgia De Berardis M.Sc.,
  5. Monica Franciosi M.Sc.,
  6. Maria C.E. Rossi M.Sc.,
  7. Michele Sacco M.D.,
  8. Antonio Nicolucci M.D.§,*

Article first published online: 24 OCT 2005

DOI: 10.1002/cncr.21474

Issue

Cancer

Cancer

Volume 104, Issue 11, pages 2334–2339, 1 December 2005

Additional Information

How to Cite

Belfiglio, M., Valentini, M., Pellegrini, F., De Berardis, G., Franciosi, M., Rossi, M. C.E., Sacco, M. and Nicolucci, A. (2005), Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer, 104: 2334–2339. doi: 10.1002/cncr.21474

Author Information

  1. Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy

  1. §

    Fax (011) 39 0872 570263

*Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale, 8/A – 66030 S. Maria Imbaro, Italy

  1. †

    Part of this study was presented in abstract form at the ASCO, 2005 Annual Meeting, Orlando, Florida 13–17 May, 2005.

  2. ‡

    Participating clinicians: Giampaolo Sacchetto, Loredana De Filippi, Alba (CN); Francesco Di Vito, Mariella Cucchi, Aosta; Giuseppe Di Biagio, Assisi (PG); Franco Testore, Asti; Luciano Isa, Gorgonzola (MI); Tonino Pedicini, Claudia Corbo, Antonio Febbraro, Benevento; Patrizia Marpicati, Giovanni Marini, Edda Simoncini, Brescia; Mario Costanzo, Catania; Ettore Cianchetti, Simona Grossi, Paolo Noccioli, Ortona (CH); Donata Tabiadon, Riccardo Valsecchi, Gino Luporini, Milano; Giordano Beretta, Cinisello Balsamo (MI); Fulvio Peradotto, Cuorgné (TO); Angelo Gambi, M. Cristina Cappelli, Flavia Foglietta, Faenza (RA); Monica Indelli, Caterina Modonesi, Ferrara; M. Antonietta De Meo, Giuseppe Cardi, Formia (LT); Giorgio Baratelli, Gravedona (CO); Liberato Di Lullo, Isernia; Giampaolo De Rubeis, L'Aquila; Stefano Graziani, Lanciano (CH); Michele Antonello, Giambeppi Pizzi, Mestre (VE); Elisa Locatelli, Milano; Vito Schena, Sergio Peonetto, Patrizia Grace Bianchi, Milano; Francesco Arceri, Novara; Paola Viola, Rho (MI); Mauro Antimi, Mauro Minelli, Vincenzo Bellini, Giuseppe Marinuzzi, Roma; Nina Olmeo, Antonio Contu, Sassari; Luciano Galletto, Marcella Sussio, Savigliano (CN); Fabrizio Fracchia, Raffaella Fiorella, Torino; Giorgio Giardina, Torino; Maria Grazia Pacquola, Anna Tava, Tortona (AL); Antonella Richetti, Marinella Molteni, Varese; Riccardo Samaritani, Roma; Attilio D'Arrigo, Ivrea (TO); Enrico Ansaldi, Cirié (TO); Sano Pasqualucci, Carlo Floris, Maria Cristina Cherchi, Enrichetta Valle, Cagliari; Italo Rasciale, Antonello Conte, Lorena Biasizzo, Udine; Antonio Tedde, Alberto Desogus, Marco Pintus, Cagliari; Giovanni Ambrosini, Orazio Caffo, Trento; Aurora Ferrari, Vittorio Corsetti, Ileana Capata, Calcinato (BS); Pietro Masullo, Francesco D'Episcopo, Vallo della Lucania (SA); Giorgio Mustacchi, Michela Muggia, Trieste; Maria Concetta Chetrí, Brindisi; Giuseppe Serravezza, Antonella Elia, Giuseppe Quarta, Casarano (LE); Stefano Bravi, Franco Biagioni, Città di Castello (PG); Antonio Rulli, Annarita Vento, Paola Naninato, Perugia; Virginia Liguori, Candida Mastroianni, Salvatore Palazzo, Cosenza; Enza Defabiani, Mario Campogrande, Torino.

Publication History

  1. Issue published online: 18 NOV 2005
  2. Article first published online: 24 OCT 2005
  3. Manuscript Accepted: 6 JUL 2005
  4. Manuscript Revised: 8 JUN 2005
  5. Manuscript Received: 14 APR 2005

Funded by

  • AstraZeneca Italia

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (92K)

REFERENCES

  • 1
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Treatment of early breast cancer. Vol. 1. Worldwide evidence, 1985–1990. Oxford: Oxford University Press, 1990.
  • 2
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992; 339: 1–15.
  • 3
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998; 351: 1451–1467.
  • 4
    Sacco M, Valentini M, Belfiglio M, et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol. 2003; 21: 2276–2281.
  • 5
    Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst. 1996; 88: 1834–1839.
  • 6
    Delozier T, Spielmann M, Mace-Lesec'h J, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. J Clin Oncol. 2000; 18: 3507–3512.
  • 7
    Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996; 88: 1543–1549.
  • 8
    International Union Against Cancer. TNM. Classification of malignant tumours. Berlin: Springer, 1987.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457–481.
  • 10
    Cox DR. Regression models and life tables. J R Stat Soc (B). 1972; 34: 187–220.
  • 11
    Nicolucci A, Belfiglio M, Pellegrini F, et al. In replay. J Clin Oncol. 2004; 22: 1165.
  • 12
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081–1092.
  • 13
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60–62.
  • 14
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687–717.
View Full Article (HTML) Get PDF (92K)